JP2005500012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500012A5 JP2005500012A5 JP2002569878A JP2002569878A JP2005500012A5 JP 2005500012 A5 JP2005500012 A5 JP 2005500012A5 JP 2002569878 A JP2002569878 A JP 2002569878A JP 2002569878 A JP2002569878 A JP 2002569878A JP 2005500012 A5 JP2005500012 A5 JP 2005500012A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- seq
- nuclear hormone
- hormone receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 17
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 17
- 108020001756 ligand binding domains Proteins 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 3
- 238000009739 binding Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000031295 Animal disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000031018 biological processes and functions Effects 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000017455 cell-cell adhesion Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105402.2A GB0105402D0 (en) | 2001-03-05 | 2001-03-05 | Novel proteins |
| PCT/GB2002/000948 WO2002070559A2 (en) | 2001-03-05 | 2002-03-05 | Nuclear hormone receptor ligand binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500012A JP2005500012A (ja) | 2005-01-06 |
| JP2005500012A5 true JP2005500012A5 (enExample) | 2005-12-22 |
Family
ID=9909998
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002570600A Pending JP2005500015A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
| JP2002569878A Pending JP2005500012A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
| JP2002569876A Pending JP2005500010A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002570600A Pending JP2005500015A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569876A Pending JP2005500010A (ja) | 2001-03-05 | 2002-03-05 | 核内ホルモンレセプターリガンド結合ドメイン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040249123A1 (enExample) |
| EP (3) | EP1370584A2 (enExample) |
| JP (3) | JP2005500015A (enExample) |
| AU (3) | AU2002237421A1 (enExample) |
| CA (3) | CA2439205A1 (enExample) |
| GB (1) | GB0105402D0 (enExample) |
| WO (3) | WO2002070559A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322203A3 (en) * | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2007514406A (ja) * | 2003-10-29 | 2007-06-07 | エヴォテック ニューロサイエンシス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒトｄａｘ−１遺伝子およびタンパク質の神経変性疾患に関する診断的および治療的使用 |
| WO2005100396A1 (en) * | 2004-04-16 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoid x receptor alpha (rxra) |
| LT2956175T (lt) | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
| EA201891589A1 (ru) | 2016-01-08 | 2019-01-31 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Условно активные гетеродимерные полипептиды и способы их применения |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712381A (en) * | 1994-10-19 | 1998-01-27 | Genetics Institute, Inc. | MADD, a TNF receptor death domain ligand protein |
| WO1998049276A1 (en) * | 1997-04-28 | 1998-11-05 | Helix Research Institute | Serine/threonine protein kinase |
| DE19816395A1 (de) * | 1998-04-03 | 1999-10-07 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Ovar-Normalgewebe |
-
2001
- 2001-03-05 GB GBGB0105402.2A patent/GB0105402D0/en not_active Ceased
-
2002
- 2002-03-05 EP EP02701458A patent/EP1370584A2/en not_active Withdrawn
- 2002-03-05 AU AU2002237421A patent/AU2002237421A1/en not_active Abandoned
- 2002-03-05 CA CA002439205A patent/CA2439205A1/en not_active Abandoned
- 2002-03-05 US US10/469,865 patent/US20040249123A1/en not_active Abandoned
- 2002-03-05 WO PCT/GB2002/000948 patent/WO2002070559A2/en not_active Ceased
- 2002-03-05 JP JP2002570600A patent/JP2005500015A/ja active Pending
- 2002-03-05 JP JP2002569878A patent/JP2005500012A/ja active Pending
- 2002-03-05 EP EP02703732A patent/EP1373315A2/en not_active Withdrawn
- 2002-03-05 AU AU2002234786A patent/AU2002234786A1/en not_active Abandoned
- 2002-03-05 EP EP02703738A patent/EP1373317A2/en not_active Withdrawn
- 2002-03-05 JP JP2002569876A patent/JP2005500010A/ja active Pending
- 2002-03-05 CA CA002439196A patent/CA2439196A1/en not_active Abandoned
- 2002-03-05 CA CA002439192A patent/CA2439192A1/en not_active Abandoned
- 2002-03-05 AU AU2002237415A patent/AU2002237415A1/en not_active Abandoned
- 2002-03-05 US US10/469,866 patent/US20040249132A1/en not_active Abandoned
- 2002-03-05 WO PCT/GB2002/000937 patent/WO2002070557A2/en not_active Ceased
- 2002-03-05 WO PCT/GB2002/000986 patent/WO2002070563A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walter et al. | Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein. | |
| JP2015530390A5 (enExample) | ||
| JP2002508970A5 (enExample) | ||
| JP2002508183A5 (enExample) | ||
| Zhang et al. | Purification and characterization of a DNA-binding heterodimer of 52 and 100 kDa from HeLa cells | |
| JP2006502702A5 (enExample) | ||
| JP2004512010A5 (enExample) | ||
| JP2005500012A5 (enExample) | ||
| JP2004526421A5 (enExample) | ||
| JP2005500015A5 (enExample) | ||
| JP2005500010A5 (enExample) | ||
| Liu et al. | Preparation of β2-homologous amino acids bearing polar side chains via a collective synthesis strategy | |
| JP2005528083A5 (enExample) | ||
| JP2008517605A5 (enExample) | ||
| JP2004535161A5 (enExample) | ||
| JP2005500013A5 (enExample) | ||
| JP2008517616A5 (enExample) | ||
| JP2007536910A5 (enExample) | ||
| JP2005500014A5 (enExample) | ||
| CA2400117A1 (en) | Novel collagen-like protein clac, a precursor thereof, and genes encoding the same | |
| JP2008509659A5 (enExample) | ||
| JP2005500820A5 (enExample) | ||
| JP2005500011A5 (enExample) | ||
| Saint Martín et al. | Identification of Dp71e, a new dystrophin with a novel carboxy‐terminal end | |
| Trasatti et al. | Rational design of peptide affinity ligands for the purification of therapeutic enzymes |